Bioprinted Organs: Timeline & Skin Regeneration News
- Vilnius-based Vital3D is pioneering bioprinting techniques, envisioning a future where human organs can be created for transplants within 10 years.The company is currently developing functional tissue constructs using...
- Vidmantas Šakalys, CEO of Vital3D, was inspired to develop 3D-printed kidneys after losing a mentor to cancer.
- VitalHeal contains growth factors to speed up skin regeneration.
Vital3D is revolutionizing medicine, aiming to bioprint human organs within a decade, starting with advanced skin regeneration.This Lithuanian startup is developing VitalHeal, a bioprinted wound patch for dogs designed to slash healing times and infection risks, targeting the booming $2.1 billion animal wound care market. Their innovative approach uses a unique laser system for precise 3D cell and biomaterial deposition. The journey doesn’t stop there; Vital3D is also exploring organoids for cancer drug testing and bioprinted stents. News Directory 3 covers this game-changing tech poised to transform healthcare. Discover how this pioneering work could soon alleviate organ shortages.
Vital3D Eyes Human Organ Transplants via Bioprinting, Starting With Dog Skin
Updated May 29, 2025
Vilnius-based Vital3D is pioneering bioprinting techniques, envisioning a future where human organs can be created for transplants within 10 years.The company is currently developing functional tissue constructs using a unique laser system that deposits living cells and biomaterials in precise 3D patterns. their initial focus? Regenerating dog skin with a bioprinted wound patch.
Vidmantas Šakalys, CEO of Vital3D, was inspired to develop 3D-printed kidneys after losing a mentor to cancer. Before tackling complex organs,Vital3D is launching VitalHeal,a bioprinted wound patch for pets,primarily dogs,with human applications to follow. Šakalys calls VitalHeal a crucial “first step” toward printing organs.
VitalHeal contains growth factors to speed up skin regeneration. Its porous surface allows air circulation while blocking bacteria. Vital3D reports the patch can cut healing time from 10-12 weeks to four to six, reduce infection risk from 30% to under 10%, and decrease vet visits and surgery times.
The animal wound care market is expected to grow significantly, reaching $2.1 billion by 2030. Vital3D estimates an initial serviceable addressable market of €76.5 million across the European Union and the U.S., aiming to sell 100,000 units by 2027-2028. While the patches will retail for about €300, Vital3D says they could reduce overall treatment costs for pet owners.
Trials on dogs are scheduled to begin this summer in Lithuania and the United Kingdom. A non-degradable patch is slated to launch in Europe next year, followed by a biodegradable version. The company then intends to adapt the technology for human wound care, initially targeting diabetic patients with impaired healing.
Šakalys said printing organs for transplantation is a challenging task. He added that it is still 10 or 15 years away,and as a commercial entity,they need to have commercially available products earlier.
Vital3D is also collaborating with Lithuania’s National Cancer Institute to develop organoids for cancer drug testing and is working on bioprinted stents. Šakalys said their ultimate goal is organ printing for transplants, which could alleviate the global shortage of transplantable organs.
Šakalys said that bioprinting can bring a lot of benefits to society, not just for transplants, but also for tissue engineering.
What’s next
Looking ahead, Vital3D plans to tackle vascularization and cell differentiation to refine its bioprinting process, possibly easing the shortage of organs for transplant and advancing personalized medicine.